Expert commentary: An endocrinologist's view of the CAROLINA trial
Sanjay Kalra tells us why he is so reassured by the findings of the CAROLINA trial pitting linagliptin against glimepiride (2:38).
- News story | CAROLINA shows neutral cardiovascular profile for modern sulfonylurea
- Clinical takeaway | WATCH: John Wilding outlines the key take-home message from the CAROLINA trial
- News story | Real-world hypoglycemia data support continued sulfonylurea role in type 2 diabetes
- News story | TOSCA.IT: Similar long-term CV safety profile for pioglitazone, sulfonylurea